These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 10763395

  • 1. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
    Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L.
    CMAJ; 2000 Apr 04; 162(7):977-83. PubMed ID: 10763395
    [Abstract] [Full Text] [Related]

  • 2. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA.
    Cancer; 2006 Jun 15; 106(12):2603-9. PubMed ID: 16700037
    [Abstract] [Full Text] [Related]

  • 3. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E, Sigbjarnarson HP, Tomasson J, Benediktsdottir KR, Tryggvadottir L, Hrafnkelsson J, Olafsdottir EJ, Tulinius H, Jonasson JG.
    Scand J Urol Nephrol; 2006 Jun 15; 40(4):265-71. PubMed ID: 16916765
    [Abstract] [Full Text] [Related]

  • 4. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
    McNaughton-Collins M, Walker-Corkery E, Barry MJ.
    J Natl Cancer Inst Monogr; 2004 Jun 15; (33):78-101. PubMed ID: 15504921
    [Abstract] [Full Text] [Related]

  • 5. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
    Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J.
    J Urol; 2007 Mar 15; 177(3):932-6. PubMed ID: 17296379
    [Abstract] [Full Text] [Related]

  • 6. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC.
    Cancer; 2007 Apr 01; 109(7):1273-8. PubMed ID: 17315165
    [Abstract] [Full Text] [Related]

  • 7. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM, Porter MP, Soloway MS.
    J Urol; 2008 Nov 01; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [Abstract] [Full Text] [Related]

  • 8. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H.
    BJU Int; 2005 Apr 01; 95(6):751-6. PubMed ID: 15794776
    [Abstract] [Full Text] [Related]

  • 9. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
    Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, Carroll PR.
    J Urol; 2005 Apr 01; 173(4):1126-31. PubMed ID: 15758720
    [Abstract] [Full Text] [Related]

  • 10. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
    Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM.
    Am J Med; 2006 May 01; 119(5):418-25. PubMed ID: 16651054
    [Abstract] [Full Text] [Related]

  • 11. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.
    J Urol; 2005 Dec 01; 174(6):2181-5. PubMed ID: 16280760
    [Abstract] [Full Text] [Related]

  • 12. Cumulative cost pattern comparison of prostate cancer treatments.
    Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR.
    Cancer; 2007 Feb 01; 109(3):518-27. PubMed ID: 17186528
    [Abstract] [Full Text] [Related]

  • 13. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT.
    J Natl Cancer Inst; 2006 Aug 16; 98(16):1134-41. PubMed ID: 16912266
    [Abstract] [Full Text] [Related]

  • 14. Prostate biopsy: who, how and when. An update.
    Djavan B, Milani S, Remzi M.
    Can J Urol; 2005 Feb 16; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [Abstract] [Full Text] [Related]

  • 15. The cost of prostate cancer chemoprevention: a decision analysis model.
    Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y.
    Cancer Epidemiol Biomarkers Prev; 2006 Aug 16; 15(8):1485-9. PubMed ID: 16896037
    [Abstract] [Full Text] [Related]

  • 16. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ.
    J Urol; 2006 Oct 16; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [Abstract] [Full Text] [Related]

  • 17. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
    Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H.
    J Urol; 2002 Aug 16; 168(2):525-9. PubMed ID: 12131302
    [Abstract] [Full Text] [Related]

  • 18. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S.
    Contemp Clin Trials; 2009 Jan 16; 30(1):81-7. PubMed ID: 18783735
    [Abstract] [Full Text] [Related]

  • 19. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA, Cowan JE, Smith JA, Carroll PR, CaPSURE Investigators.
    J Urol; 2008 Oct 16; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [Abstract] [Full Text] [Related]

  • 20. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H.
    J Urol; 2002 Jan 16; 167(1):117-22. PubMed ID: 11743287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.